Sunho Biologics Inc
Company Profile
Business description
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
Contact
No. 198 Peninsula Middle Road, Dipu Street
Room 302, Building 3
Anji County
Zhejiang Province
Huzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
124
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,648.80 | 198.80 | -2.53% |
| CAC 40 | 7,017.50 | 257.45 | -3.54% |
| DAX 40 | 20,010.11 | 631.61 | -3.06% |
| Dow JONES (US) | 37,822.40 | 2,723.53 | -6.72% |
| FTSE 100 | 7,802.51 | 252.47 | -3.13% |
| HKSE | 20,223.57 | 2,626.24 | -11.49% |
| NASDAQ | 15,556.05 | 994.56 | -6.01% |
| Nikkei 225 | 33,030.66 | 749.92 | -2.22% |
| NZX 50 Index | 11,922.90 | 302.38 | -2.47% |
| S&P 500 | 5,041.94 | 32.14 | -0.63% |
| S&P/ASX 200 | 7,451.20 | 216.60 | -2.82% |
| SSE Composite Index | 3,120.15 | 23.58 | 0.76% |